Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxi...

Full description

Saved in:
Bibliographic Details
Main Authors MIROSLAV TERINEK, ACHIM FEURER, MARCO HENNEBOHLE, HERVE SIENDT, CESARE MONDADORI, ULRICH ABEL, HOLGER HERZNER, CHRISTIAN RUMMEY, BARBARA HOFFMANN-ENGER, HOLGER DEPPE, SONJA NORDHOFF, INGE OTT, GUNTHER METZ, MICHAEL SOEBERDT, PHILIPP WEYERMANN
Format Patent
LanguageEnglish
Published 24.03.2011
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression.
Bibliography:Application Number: AU20080231977